PMID- 34819720
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 1177-5475 (Print)
IS  - 1177-5491 (Electronic)
IS  - 1177-5475 (Linking)
VI  - 15
DP  - 2021
TI  - Treatment with Ixekizumab Following Secukinumab Failure in Patients with 
      Psoriatic Arthritis: Real-Life Experience from a Resistant Population.
PG  - 463-470
LID - 10.2147/BTT.S326792 [doi]
AB  - OBJECTIVE: To assess the clinical response to ixekizumab following secukinumab 
      failure in patients with psoriatic arthritis. METHODS: A retrospective 
      multi-center observational study included psoriatic arthritis (PsA) patients with 
      a history of treatment with secukinumab, further treated with ixekizumab. Primary 
      endpoint was primary response to treatment (drug survival > 6 months); secondary 
      endpoints were changes in disease activity indices from initiation of ixekizumab 
      to 6 and 12 months later and overall drug survival. RESULTS: Of 23 PsA patients, 
      86% (n = 20) received more than two TNF inhibitors (TNFi). Median secukinumab 
      treatment time was 15 months (IQR 10-21.5 months). Subsequently, 19 patients 
      (83%) had a primary response to ixekizumab. Overall treatment duration during 
      follow-up period for primary responders was 14 months (IQR 10-20.5). Reasons for 
      ixekizumab cessation were worsening psoriasis (27%), peripheral arthritis (27%), 
      both (47%), worsening of axial disease (13%), and adverse events (6%). Articular 
      disease indices including Disease Activity Index for Psoriatic Arthritis (DAPSA), 
      tender joints count (TJC) and Simplified Disease Activity Index (SDAI) were 
      significantly lower at 6 and 12 months (DAPSA 1.5-2 levels reduction; p = 0.018 
      and 1-1.5 levels reduction; p = 0.031, respectively; TJC -2.16 [-4.0, -0.3]; p = 
      0.025 and -1.69 [-3.09, -0.28]; p = 0.022, respectively; SDAI -10.13 [-16.4, 
      -3.8], p = 0.003 and -12.2 [-17.1, -7.2], p = 0.0002, respectively). PASI75 at 6 
      and 12 months was achieved by 63% and 57%, respectively, and PASI100 at 6 and 12 
      months by 31% and 21%, respectively. CONCLUSION: Patients with resistant PsA, 
      including inadequate response to secukinumab, demonstrated a good response to 
      ixekizumab, albeit limited on time. Within class switch from secukinumab to 
      ixekizumab may be a plausible therapeutic option in PsA patients following 
      secukinumab failure.
CI  - (c) 2021 Berman et al.
FAU - Berman, Julia
AU  - Berman J
AUID- ORCID: 0000-0002-3963-9026
AD  - Department of Medicine 'T', Sourasky Medical Center, Tel Aviv, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Furer, Victoria
AU  - Furer V
AUID- ORCID: 0000-0001-5193-4207
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Department of Rheumatology, Sourasky Medical Center, Tel Aviv, Israel.
FAU - Berman, Mark
AU  - Berman M
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Department of Rheumatology, Sourasky Medical Center, Tel Aviv, Israel.
FAU - Isakov, Ofer
AU  - Isakov O
AD  - Department of Medicine 'T', Sourasky Medical Center, Tel Aviv, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Zisman, Devy
AU  - Zisman D
AUID- ORCID: 0000-0003-0523-2292
AD  - Rheumatology Unit, Carmel Medical Center, Haifa, Israel.
AD  - The Ruth and Bruce Rappaport Faculty of Medicine,Technion, Haifa, Israel.
FAU - Haddad, Amir
AU  - Haddad A
AD  - Rheumatology Unit, Carmel Medical Center, Haifa, Israel.
FAU - Elkayam, Ori
AU  - Elkayam O
AUID- ORCID: 0000-0001-9329-3639
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Department of Rheumatology, Sourasky Medical Center, Tel Aviv, Israel.
LA  - eng
PT  - Journal Article
DEP - 20211118
PL  - New Zealand
TA  - Biologics
JT  - Biologics : targets & therapy
JID - 101321511
PMC - PMC8608411
OTO - NOTNLM
OT  - antibodies
OT  - arthritis
OT  - duration of therapy
OT  - humanized
OT  - ixekizumab
OT  - monoclonal
OT  - psoriasis
OT  - psoriatic
OT  - secukinumab
COIS- Dr Victoria Furer report personal fees from Novartis, personal fees from Eli 
      Lilly, during the conduct of the study. Dr Devy Zisman report grants from Pfizer, 
      personal fees from Eli Lilly, personal fees from Novartis, personal fees from 
      AbbVie, outside the submitted work. Professor Ori Elkayam reports has received 
      honorary fees as a speaker and as consultant in advisory board from Lilly and 
      Novartis. The authors report no other conflicts of interest in this work.
EDAT- 2021/11/26 06:00
MHDA- 2021/11/26 06:01
PMCR- 2021/11/18
CRDT- 2021/11/25 06:31
PHST- 2021/07/15 00:00 [received]
PHST- 2021/09/18 00:00 [accepted]
PHST- 2021/11/25 06:31 [entrez]
PHST- 2021/11/26 06:00 [pubmed]
PHST- 2021/11/26 06:01 [medline]
PHST- 2021/11/18 00:00 [pmc-release]
AID - 326792 [pii]
AID - 10.2147/BTT.S326792 [doi]
PST - epublish
SO  - Biologics. 2021 Nov 18;15:463-470. doi: 10.2147/BTT.S326792. eCollection 2021.